The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Efficacy of ibrexafungerp for treating fungal infections in patients with AML
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the efficacy of the novel triterpenoid inhibitor ibrexafungerp, to treat fungal infections in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Zucenka discusses risk factors for the development of fungal infections in these patients and explains real-world data showing efficacy of ibrexafungerp in these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
